10 RESULTS
COMMENT Goedert’s group, including colleagues from Tokyo and Indiana, has made a seminal contribution to the field, and far beyond it. It is of particular note that “The three-dimensional structures look nothing like those formed by Aβ or tau fibrils, or indeed ...
COMMENT The article by Ayton et al. is pivotal to our understanding of iron’s role in Alzheimer’s disease (AD) pathology and dementia. This exciting work connects another important recent research on microRNA (miR-346) to the field. Let us try to iron out the ...
COMMENT To alleviate BACE1 trials disappointment, I suggest not missing the APPointment. BACE1 inhibition should remain a viable strategy even though recently tested BACE1 inhibitors worsened cognition. We must be brave to tackle the “bumps” along the way of ...
COMMENT The recent structural studies illuminate that Pick’s disease is picky in selecting a repeat to fold into tau aggregates. Falcon and colleagues have demonstrated an exciting difference at the molecular level between Alzheimer’s disease and Pick’s disease ...
COMMENT To iron out a few kinks in Alzheimer’s disease field, Lumsden et al. have built an iron framework that might unite, functionally, several known mutations associated with the familial form of AD. It is timely and thought provoking. The “traditional” ...
COMMENT The increased funding for Alzheimer’s research is a very welcome and encouraging piece of news. There is little doubt that hard work from activists, researchers, editorials, and public support played their parts. Now it is up to NIH to effectively utilize ...
COMMENT Elenbecestat trial starts with hope and elan We were pleased to hear that elenbecestat (Eisai/Biogen) has passed Phase 2 trials with no apparent toxicity and successful changes in “pathology”—although not in actual cognitive symptoms. Several candidate ...
COMMENT A BACE1 inhibitor failure is an opportunity for selective BACE1 inhibition. Janssen recently announced that it terminated atabecestat development. The announcement further stated that serious elevations in liver enzymes were detected in some patients ...
COMMENT Merck pushing forward on clinical trials for a BACE1 inhibitor in such late stages of AD is certainly puzzling, as others have already noted. It is to be expected that, once Aβ has plateaued and sufficient Aβ-related damage has been done, there will be ...
COMMENT Comment by Debomoy Lahiri and Bryan Maloney The previously proposed LEARn (Latent Early-life Associated Regulation) pathway may explain the recently featured results from Chumley and Kahn and from Knuessel et al. regarding infection and AD. Work such as ...
